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Article Information  ABSTRACT 
Received: 27th May 2019  Autism is a group of neurodevelopment disorders characterized by impaired communication, 
impaired social interaction and restricted, repetitive and stereotyped patterns of behaviours or 
interests in the first 3 years of life. It shows a strong male bias and found four times more in 
males than in females. According to a study in the US, in 2014, overall 1.68% of victims were 
reported to have Autism Spectrum Disorder (ASD), whereas the percentage was increased by 
15% and 150% respectively over the year 2012 and 2000. Numerous genes have been discovered 
that have roles in ASD but still a good understanding of the pathophysiological process of ASD 
is not established. ASD costs are estimated to be approximately $250 billion annually in the U.S. 
Moreover, it is suggested that by 2025, ASD costs will rise to over $450 billion. Thus, the 
financial burden on families is increasing. There is no effective screening tool for proper 
diagnosis is available. Based on Infant Toddler Checklist (ITC) and Diagnostic and Statistical 
Manual of Mental Disorders, fifth edition (DSM-5) some tests like ADOS-G, ADI-R, CARS etc. 
are used for diagnosis. There are medications to cure symptoms but no single medication for 
ASD. However, some therapies (like ABA- Applied Behavioural Analysis, DTT- Discrete Trial 
Training, and Symptomatic treatments, etc.) are there that show positive responses towards 
improvement from a disease state. Some crucial advancement has been achieved in the last 
decades. Here in the work we have focused on the diagnostic methods and treatment available for 
the symptoms of Autism. So, it can be said that the day is not too far away when the remedy to 
cut the curse of autism will be in our hands. 
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INTRODUCTION 
Autism is a group of neurodevelopment disorders known as 
pervasive developmental disorders. These disorders are 
characterized by three main conditions: impaired 
communication, impaired reciprocal social interaction and 
restricted, repetitive and stereotyped patterns of behaviours or 
interests in the first 3 years of life. The distinctive social 
behaviours include avoidance of eye contact, problems with 
emotional control or understanding the emotions of others, and 
a markedly restricted range of activities and interests [1, 2]. 
The current prevalence of Autism Spectrum Disorder (ASD) in 
the latest large-scale surveys is about 1%- 2% of the total 
population of the world [3, 4]. The prevalence of ASD has 
increased in the past two decades [5]. Although the increase in 
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prevalence is partially the result of changes in the Diagnostic 
and Statistical Manual of Mental Disorders (DSM) and younger 
age of diagnosis, an increase in risk factors cannot be ruled out 
[6, 7]. Studies have shown, ASD has a strong male bias in its 
prevalence. It affects four times more males than females [8]. 
Their results show that girls score significantly higher in socio-
emotional reciprocity and lower in restricted and repetitive 
behaviours than boys [9]. Some researchers have suggested 
there is a possibility that the female-specific protective effects 
against ASD might exist [10]. Literature regarding ASD with 
regression has grown significantly over the past 25 years. There 
is no universally agreed definition; however, all definitions 
support that regression involves the loss of a previously 
attained skill, such as language. At present, two specified 
classes of the term regression are evident in the autism 
literature, language, and language/social regressions [11]. 
Language regression refers, to the loss of verbalizations while 
language/social regression, indicates other social behaviour 
involved in addition to the language.  
 
In 2016, there were estimated 62 million cases of ASD 
worldwide, accounting for a prevalence of 0.83% [12]. In terms 
of disease burden, ASD accounted globally for more than 9 
million Years Lived with Disability and for 121 Disability 
Adjusted Life Years per 100,000 populations [13]. In high-
income countries, ASD prevalence has been estimated to be 
about 1% across all ages [14]. However, According to a study 
in the US, in 2014, overall 1.68% of victims were reported to 
have Autism Spectrum Disorder (ASD), Whereas the 
percentage was increased by 15% and 150% respectively over 
the year 2012 and 2000 [15]. Therefore, ASD prevalence in the 
US appears to have increased in the last decades, but the causes 
of this surge are not yet fully understood. ASD costs are 
estimated to be approximately $250 billion annually in the U.S. 
Moreover, it is suggested that by 2025, ASD costs will rise to 
over $450 billion [16]. Thus, the financial burden on families is 
increasing. There is no effective screening tool for proper 
diagnosis is available. However based on Infant Toddler 
Checklist (ITC) and DSM-5, some diagnostic process has been 
developed like ADOS- G, ADI- R, CARS, GARS, DISCO and 
these are now used for diagnosis. There are some therapies 
(like ABA, Respiridone, Aripriprazole, TEACCH) that can 
suppress the symptoms of ASD but no drug has been found for 
treatment of it. 
 
HISTORY 
A Swiss psychiatrist, Paul Eugen Bleuler used the term 
“autism” to define the symptoms of schizophrenia for the first 
time in 1912 [17]. It comes from the Greek word αὐτός (autos), 
which means self. Hans Asperger adopted Bleuler’s 
terminology “autistic” in its modern sense to describe child 
psychology in 1938. Afterward, he reported about four boys 
who did not mix with their peer group and did not understand 
the meaning of the terms ‘respect’ and ‘polite’, and regard for 
the authority of an adult. The boys also showed specific 
unnatural stereotypic movements and habits. Asperger 
describes this pattern of behaviours as “autistic psychopathy”, 
which is now called Asperger’s Syndrome [18]. The person 
who first used autism in its modern sense is Leo Kanner. In 
1943, he reported about 8 boys and 3 girls who had “an innate 
inability to form the usual, biologically provided affective 
contact with people”, and introduced the label early infantile 
autism [19]. Hans Asperger and Leo Kanner have been 
considered as those who designed the basis of the modern study 
of autism. 
 
ETIOLOGY 
ASD is not a single disorder. It is a bunch of abnormalities 
cause a lack of neurodevelopment. The exact cause of autism 
and the other ASDs is still not known. The etiologic theories 
have changed over the years. It was once thought to be the 
result of faulty child-rearing. This historical psychosocial 
theory has been rejected, as research clearly indicates that the 
etiology is multi-factorial with a strong genetic basis [20]. 
 
Gene defects and chromosomal abnormality have been found in 
10%- 20% of individuals with ASD [21, 22]. Siblings born in 
families with an ASD subject have a 50 times greater risk of 
ASD, with a recurrence rate of 5%- 8% [23]. The occurrence 
rate reaches up to 82%- 92% in monozygotic twins, whereas 
1%- 10% in dizygotic twins. Genetic studies suggested that 
developmental pathways of neuronal and axonal structures 
involved in synaptogenesis altered bysingle-gene mutations 
[24-26]. In the cases related to fragile X syndrome and 
tuberous sclerosis, hyper-excitability of neocortical circuits 
caused by alterations in the neocortical excitatory or inhibitory 
balance and abnormal neural synchronization is thought to be 
the most probable mechanisms [27, 28]. Recently it has been 
found that, TSC, a disorder caused by a mutation in the TSC1 
or TSC2 gene, exhibits an increased risk of autism [29]. 
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The environmental factors can also be reasons for ASD [30]. 
Environmental risk factors include advanced parents’ age, 
pregnancy complications, and maternal conditions, organic 
toxicants, air pollution, or medication exposure during 
pregnancy [31]. In the pre and postnatal periods, these factors 
can produce an effect on brain development. Although, 
determination of the causing pathway of environmental risk 
factors is challenging as they can act directly on the CNS or by 
other biological mechanisms. Cesarean section is a cause of 
several neurodevelopment disorders, including ASD [32]. It 
can directly or indirectly change the characteristics of the 
microbiome of the intestine of the new born which can be a 
leading cause of Autism [33]. Besides that, large twin studies 
shows that the uterine environment has an important impact on 
the development of the foetus and that the mother’s health can 
deeply influence the long-term mental and physical health of 
the developing foetus [34]. However, researchers are now 
suspecting that there is a major role of multiple gene-
environmental interactions in wide inter-individual 
heterogeneity of ASD [30]. Because of the multiple risk 
factors, the actual cause of Autism is very difficult to find out. 
That is why the main cause has still not been found out. 
 
DIAGNOSIS 
Autism is one of a group of pervasive developmental disorders. 
These disorders are characterized by three main conditions like 
impaired communication, impaired reciprocal social interaction 
and restricted, repetitive and stereotyped patterns of behaviours 
or interests in the first 3 years of life [1, 2]. ASD is diagnosed 
clinically based on the presence of core symptoms. Caution is 
required at the time of diagnosis of ASD because of non-
specific manifestations in different age groups and individual 
abilities in intelligence and verbal domains. In early days the 
nonspecific signs recognized in infancy included irritability, 
passivity, and difficulties with sleeping and eating, followed by 
delays in language and social engagement. At 12 months of 
age, infants with ASD show atypical behaviours, across the 
domains of visual attention, imitation, social responses, motor 
control, and reactivity. There is also a report about atypical 
language trajectories, with mild delays at 12 months 
progressing to more severe delays by 24 months. By 3 years of 
age, the typical core symptoms such as lack of social 
communication and restricted or repetitive behaviours and 
interests are manifested [35]. 
 
There are some tests to diagnose ASD based on ICD and DSM 
that have been developed using a parent or carer interview, 
child observation, or a combination of both. The ICD and DSM 
are both discussed on Table no 1 and the diagnostic tests based 
on these two are discussed at Table no. 2 
 
TREATMENT 
ASDs are lifelong chronic disabilities. Not a single medication 
has been found that can cure ASD. However, several groups of 
medications, including atypical neuroleptics, have been used to 
treat associated behavioural problems such as aggression and 
self-injurious behaviours [41,42]. Treatment of disabling 
symptoms such as aggression, agitation, hyperactivity, 
inattention, irritability, repetitive and self-injurious behaviour 
may allow educational and behavioural interventions to 
proceed more effectively [43]. There are limited treatment 
options to suppress the symptoms associated with ASDs, 
including both symptoms related to diagnostic criteria and 
those that are considered to be a function of comorbid mental 
and medical conditions known to exacerbate the severity of 
presentation. While there are promising indications for new 
medical treatments for autism [44], a recent systematic review 
found that while many children with ASDs are treated with 
medical interventions, there is minimal evidence to support the 
benefit of most treatments [45]. There are numerous challenges 
for the identification of effective treatments for ASD. 
Systematic reviews highlight the possibility that genetic, 
environmental, cognitive, and social heterogeneity in the ASD 
phenotype produces highly variable study samples that reduce 
the potential effect size of an intervention [46]. Research has 
shown that the most effective therapy is the use of early 
intensive behavioural interventions that aim to improve the 
functioning of the affected child. These are focused on 
developing language, social responsiveness, imitation skills, 
and appropriate behaviours. Examples of these behavioural 
therapies include ABA (Applied Behaviour Analysis) and 
TEACCH (Treatment and Education of Autistic and Related 
Communication Handicapped Children). The ABA approach 
involves teaching new behaviours by various techniques and 
problem in behaviours are addressed by analyzing triggers. The 
TEACCH approach takes advantage of relative strengths in 
visual information processing using strategies such as visual 
schedules, clearly structured and organized classrooms, and 
highly structured learning activities that are broken down into 
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manageable, visually organized steps [47]. These are some 
following methods of treatment of ASD some of them have 
proven their usefulness (discussed in Table no. 3) and some of 
them will possibly prove their usefulness and still under trial 
period (discussed in Table no. 4). 
Table 1: ICD and DSM 
Classification methods  Release Date Based On Ref 
ICD- 10 (International Classification of Diseases and Related 
Health Problems - Tenth Revision) 
1990 
ICD- 11 in 2018 
1) communication  
2) social interaction 
3) presence of restricted 
[36] 
DSM-5 (Diagnostic and Statistical Manual of Mental 
Disorders, fifth edition) 
2013 
1) social communication 
2) restricted 
[36] 
 
Table 2: Diagnostic tests based on ICD and DSM 
Diagnostic Test Release Date Assessment parameters  
Duration of 
test  
Applied age 
group 
Ref. 
ADOS- G  
(Autism Diagnostic 
Observation Schedule 
‐ Generic) 
1989 
Commercially 
available in 
2011 
1) social interaction  
2) communication  
3) play 
4) imaginative use of materials 
30 to 60 
minutes 
Under 6 
years 
[36, 
37] 
ADI‐R 
(Autism Diagnostic 
Interview ‐ Revised) 
1994 
1) reciprocal social interaction 
2) communication and language 
3) restricted and repetitive stereotyped 
interests and behaviours 
2 to 18 months 
At least 24 
months 
[38] 
CARS 
(Childhood Autism 
Rating Scale) 
Second edition 
in 2010 
1)Relationship with people 
2)Imitation 
3)Emotional response 
4)Body use 
5)Object use 
6)Adaptation to change 
7)Visual  Listening response 
8)Taste-smell-touch response and use 
9)Fear and nervousness 
10)Verbal communication 
Non-verbal communication activity level 
11)Level and consistency of  
intellectual response, General impressions 
 
 
 
 
 
5 to 10 
minutes 
 
 
2 to 4 years [36] 
DISCO 
(Diagnostic Interview 
for Social and 
Communication 
Disorder) 
2012- 2013 
1) Family andmedical background  
2) Infancy 
3) Developmental skills 
4) Repetitive, stereotyped activities 
5) Emotions 
6) Maladaptive behaviour  
7)Interviewers’ Judgement of quality  
8) questions considering other psychiatric 
disorders  
9)forensic problems 
3 days 3 to 11 years [39] 
GARS 
(Gilliam Autism 
Rating Scale) 
Third edition 
2013 
1) social Interaction 
2) Communication   
3) stereotyped behaviours 
4) developmental Disturbances. 
 
 
5- 10 minutes 
3 to 22 years [36] 
3di 
(Developmental, 
Dimensional, and 
Diagnostic Interview) 
2004 
1) Severity 
2) frequency  
3) comorbidity 
 
90 minutes 
 
6 to 16 years [40] 
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Table 3: Reported beneficial therapies 
Non biological therapy 
Therapy Types Description Ref 
ABA- 
Applied 
Behavioural 
Analysis 
Discrete Trial 
Training (DTT) 
Typically conducted in a one-to-one situation at a desk or table with minimal 
distractions. It consists of five parts 1) cue, 2) prompt, 3) response, 4) 
consequence, 5) inter-trial interval. 
[48] 
Early Intensive 
Behavioural 
Intervention (EIBI) 
Based on the principles of applied behaviour analysis. Delivered for multiple 
years at an intensity of 20 to 40 hours per week for younger than 3-5 years of age. 
[49] 
Verbal Behavioural 
Intervention (VBI) 
Focused on developing and using strategies in natural settings that will be 
beneficialfor naturalistic teaching approaches. 
[50] 
Pivotal Response 
Training (PRT) 
Based on behaviour analysis principles to improve social communication skills. It 
targets areas such as motivation, responsiveness to multiple self-management, and 
social initiations. 
[51] 
Biological therapy 
Therapy Types Description Ref 
Symptomatic 
treatments 
(Psycho 
Pharmacological 
Agents) 
Respiridone First drug to be approved by the US FDA for the symptomatic treatment of 
irritability, deliberate self-injury, and aggressive behaviour in children of more than 
5 years with ASD 
[52] 
Aripriprazole Aripiprazole has also been approved by the FDA for the treatment of irritability in 
autistic children aged 6-17 years. It can reduce stereotypy, irritability, and 
hyperactivity in children aged 6-17 years 
[53] 
 
Table 4: Hypothesis based reported therapy for partial benefits 
Non biological therapy 
Therapy Type Description Ref 
Treatment And 
education of 
Autistic and 
children 
(TEACCH) 
 
It includes important elements such as the organization of the physical 
environment, predictable sequence of activities, routines with flexibility, 
structured activity systems, and visually structured activities. It also provides 
clinical services such as social play and recreation groups, parent support 
groups and training, diagnostic evaluations, individual training for high 
functioning autistic groups, and supported employment 
[54, 
55] 
 
 
 
 
Developmental 
Models 
 
 
 
Denver Model 
It uses interpersonal relationships, play and activities toremediate the main 
deficits in imitation, emotion sharing. 
[56] 
Early Start Denver 
Model (ESDM) 
ESDM is an integrative program that utilizes a combination of relationship-
based and developmental approaches plus ABA programs. It includes parents 
as therapists. 
[57] 
Developmental 
Individual 
Difference (DIR) 
It focuses on “floor time” play sessions and other strategies that enhance 
relationships and emotional and social interactions in order to facilitate 
cognitive and emotional development. It also addresses deficits in motor 
planning and sequencing, auditory processing and language, visual spacing 
processing, and sensory modulation 
[54] 
Relationship 
Developmental 
This, allows the child to discover the value of positive interpersonal activity 
and thus helps him or her to become more motivated in learning the skills to 
[54] 
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Intervention (RDI) sustain this relationship 
Responsive 
Technology (RT) 
This is implemented by parents in order to address the language, cognitive, 
and social-emotional needs of young children with developmental problems 
[58] 
Picture Exchange 
Commutation 
System (PECS) 
 
The purpose is to teach children with autism to initiate communication by 
handing a picture to a communication partner in exchange for the desired item. 
The picture may be used instead of or in conjugation with speech 
[59] 
Social ABCs by 
parents or 
caregiver 
 
The treatment group experienced a favourable response in these features: (1) 
child functional vocal responsiveness to parent prompts, (2) child vocal 
initiations, (3) parent smiling and (4) fidelity of implementation 
[60] 
Parents Mediated 
Communication 
 
parents are trained by the therapist with the aim to first increase parental 
sensitivity and responsiveness to child communication and reduce mistimed 
parental responses 
[61] 
Caregiver 
Mediated 
Communication 
 
In this method caregivers actively coached the children everyday activities like 
watering plants, grooming, and helping with laundry 
[62] 
Biological Therapy 
Therapy Types Description Ref 
Potential 
Psychopharmacologic 
Agents 
Stimulants 
stimulants such as methylphenidate improves symptoms of hyperactivity, 
impulsivity, and inattention in children with ASD 
[63] 
α Adrenergic 
Agonist 
Alpha-2 adrenergic agonists such as guanfacine and clonidine have been 
used to manage symptoms of hyperactivity, impulsivity, and inattention in 
children with ASD 
[64] 
Serotonin Specific 
Reuptake Inhibitors 
Fluoxetine in children with ASD showed beneficial results in reducing 
repetitive and other maladaptive behaviors 
[65] 
 
CONCLUSION 
Autism is now a very common neurodevelopment disorder 
characterized by three core deficits: impaired communication, 
impaired reciprocal social interaction and restricted, repetitive 
and stereotyped patterns of behaviours or interests. It affects 
children aged less than 3 years. Sometimes lack off of 
importance the diagnosis of Autism becomes late. The 
prevalence rate is around 1 in 68 and continuously increasing in 
the US. With increasing the number of autism affected children 
and the treatment cost the burden on the families is increasing. 
The proper cause of ASD is still not known and there is no 
actual treatment to fully cure this disorder. However, we live in 
the era of modern science where the medical field has shown 
tremendous growth. There is not a possible treatment for 
Autism but now the symptoms can be treated by different 
therapies that have been discussed above. Autism is a lifelong 
disorder so it is very necessary to identify it as soon as possible 
so it is very important for parents to understand the problems. It 
is an era of internet, so for educating the parents about the 
disorder, there are many websites like “autism-society.org”, 
“autismspeaks.org”, “helpguide.org”, “cdc.gov” etc. For 
increasing the awareness of Autism some organizations like 
“Autism-India, Autism Society of India, National Autistic 
Society, Autism Speaks, Autism Society of America, Autistic 
Self Advocacy Network, Organization for Autism Research, 
Autism Research Institute, Autism Europe, Autism for 
freedom, etc.” are working very hard and they are also getting 
their results of hard work.  
 
Every year on 2
nd
 April “World Autism Awareness Day” is 
celebrated to educate people and to increase awareness about 
Autism all over the world.With these many advancements, it 
can be said that the day is not too far away when the remedy to 
cut the curse of autism will be in our hands. 
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